SCHEMBL1127315

SCHEMBL1127315

CCOC(=O)C(C(=O)OCC)C(=O)C(Cc1ccc(OC)cc1)c1ccccn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
GAA P10253 2/20 0.47
TSHR P16473 1/20 0.47
EPHX2 P34913 1/20 0.43
LMNA P02545 3/20 0.42
HPGD P15428 3/20 0.42
ALDH1A1 P00352 4/20 0.41
LDHA P00338 1/20 0.41
KDM4E B2RXH2 3/20 0.41
NPSR1 Q6W5P4 2/20 0.41
MAPT P10636 1/20 0.41
HTT P42858 1/20 0.41
CCR6 P51684 1/20 0.41
HKDC1 Q2TB90 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
F2 P00734 1/20 0.40
SLC10A1 Q14973 1/20 0.40
PPARG P37231 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1127316 0.89 MEN1 (0.52) MEN1KMT2ASMN1; SMN2GAATSHR
SCHEMBL1127831 0.88 KMT2A (0.45) MEN1KMT2ASMN1; SMN2GAATSHR
SCHEMBL1127390 0.87 KMT2A (0.48) MEN1KMT2ASMN1; SMN2GAAEPHX2
SCHEMBL1127508 0.85 GAA (0.46) MEN1KMT2ASMN1; SMN2GAAHPGD
SCHEMBL1127436 0.84 MEN1 (0.46) MEN1KMT2ASMN1; SMN2GAALMNA
SCHEMBL1127320 0.82 TSHR (0.44) MEN1KMT2AGAATSHRALDH1A1
SCHEMBL4281403 0.82 KMT2A (0.46) MEN1KMT2ASMN1; SMN2GAAALDH1A1
SCHEMBL1127495 0.82 KMT2A (0.47) MEN1KMT2ASMN1; SMN2GAALMNA
SCHEMBL13662306 0.81 TSHR (0.48) MEN1KMT2ASMN1; SMN2TSHRLMNA
SCHEMBL1127510 0.81 SMN1; SMN2 (0.46) MEN1KMT2ASMN1; SMN2GAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2283002-A2 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION Intermune, Inc. (US) 2011-02-16 EP disclosed
WO-2009134616-A2 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-11-05 WO disclosed
WO-2009134616-A2 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-11-05 WO disclosed
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication INTERMUNE, INC. (US) 2009-10-15 US disclosed
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication INTERMUNE, INC. (US) 2009-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication EIF2AK2, HAVCR2, HDGF MEN1 4723/4885KMT2A 2735/4885SMN1; SMN2 3563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.